AstraZeneca PLC (AZN)vsCronos Group Inc (CRON)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
CRON
Cronos Group Inc
$3.14
-0.63%
HEALTHCARE · Cap: $1.16B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 34166% more annual revenue ($61.37B vs $179.09M). CRON leads profitability with a 39.1% profit margin vs 17.0%. CRON trades at a lower P/E of 16.5x. CRON earns a higher WallStSmart Score of 61/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CRON
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for CRON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Keeps 39 of every $100 in revenue as profit
Revenue surging 58.4% year-over-year
Earnings expanding 126.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -0.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : CRON
The strongest argument for CRON centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.1% and operating margin at 15.4%. Revenue growth of 58.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : CRON
The primary concerns for CRON are Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while CRON is a growth play — different risk/reward profiles.
CRON carries more volatility with a beta of 1.28 — expect wider price swings.
CRON is growing revenue faster at 58.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
CRON scores higher overall (61/100 vs 60/100), backed by strong 39.1% margins and 58.4% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Cronos Group Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?